AU2010294292B2 - Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer - Google Patents

Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Download PDF

Info

Publication number
AU2010294292B2
AU2010294292B2 AU2010294292A AU2010294292A AU2010294292B2 AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2 AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2
Authority
AU
Australia
Prior art keywords
alkyl
benzenesulfonamide
methyl
butan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010294292A
Other languages
English (en)
Other versions
AU2010294292A1 (en
Inventor
Karen Miller-Moslin
Bakary-Barry Toure
Michael Scott Visser
Naeem Yusuff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010294292A1 publication Critical patent/AU2010294292A1/en
Application granted granted Critical
Publication of AU2010294292B2 publication Critical patent/AU2010294292B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010294292A 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Ceased AU2010294292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
US61/241,251 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2010294292A1 AU2010294292A1 (en) 2012-03-01
AU2010294292B2 true AU2010294292B2 (en) 2013-07-18

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010294292A Ceased AU2010294292B2 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer

Country Status (12)

Country Link
US (1) US8809352B2 (OSRAM)
EP (1) EP2475661B1 (OSRAM)
JP (1) JP2013504536A (OSRAM)
KR (1) KR20120078715A (OSRAM)
CN (1) CN102498111A (OSRAM)
AU (1) AU2010294292B2 (OSRAM)
BR (1) BR112012005343A2 (OSRAM)
CA (1) CA2772989A1 (OSRAM)
EA (1) EA020586B1 (OSRAM)
ES (1) ES2443845T3 (OSRAM)
MX (1) MX2012003007A (OSRAM)
WO (1) WO2011029842A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012209295B2 (en) * 2011-01-25 2016-06-30 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
MD4635C1 (ro) 2013-10-14 2020-01-31 Eisai R&D Management Co., Ltd. Compuşi de chinolină substituiţi selectiv
WO2015057655A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN108349924A (zh) * 2015-08-12 2018-07-31 纪念斯隆凯特林癌症中心 苯磺酰氨基-苯并呋喃衍生物及其用途
JP2019501225A (ja) * 2016-01-11 2019-01-17 メリマック ファーマシューティカルズ インコーポレーティッド Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
FI3788042T3 (fi) 2018-04-29 2025-04-07 Beigene Switzerland Gmbh Bcl-2-inhibiittoreita
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
TW202200574A (zh) 2020-04-15 2022-01-01 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487811B1 (en) * 2002-03-21 2007-09-05 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Also Published As

Publication number Publication date
ES2443845T3 (es) 2014-02-20
EA201200472A1 (ru) 2012-10-30
AU2010294292A1 (en) 2012-03-01
EP2475661B1 (en) 2013-10-23
JP2013504536A (ja) 2013-02-07
BR112012005343A2 (pt) 2016-03-22
WO2011029842A1 (en) 2011-03-17
US8809352B2 (en) 2014-08-19
KR20120078715A (ko) 2012-07-10
US20120165298A1 (en) 2012-06-28
EA020586B1 (ru) 2014-12-30
MX2012003007A (es) 2012-04-11
CN102498111A (zh) 2012-06-13
CA2772989A1 (en) 2011-03-17
EP2475661A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
AU2010294292B2 (en) Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
JP6983273B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
ES2944937T3 (es) Tienopirroles en calidad de inhibidores de la histona desmetilasa
KR102429220B1 (ko) 치환 4-페닐피페리딘, 그 제조 및 사용
WO2019158019A1 (zh) 嘧啶并环化合物及其制备方法和应用
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
ES2734268T3 (es) Derivados de urea y amida de aminoalquilpiperazinas y uso de los mismos
TW201350476A (zh) 用於調節表皮生長因子受體（ｅｇｆｒ）活性之化合物及組合物
BR112013002182B1 (pt) Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
KR20200028423A (ko) Rock의 억제제로서의 5-원 및 비시클릭 헤테로시클릭 아미드
KR20230175222A (ko) Nek7 억제제
AU2009318855A1 (en) Lactams as beta secretase inhibitors
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
JP7142010B2 (ja) メニン－ｍｌｌ相互作用のアゼパン阻害剤
CN102149706A (zh) 4-氧代-l,4-二氢-喹啉的抗肿瘤的衍生物、其制备方法和其治疗用途
US8273890B2 (en) Thiophene-imidazopyridines
EP3986405A1 (en) Compounds for inhibiting fgfr4
CN117597346A (zh) Nek7抑制剂
WO2019106368A1 (en) Pyrrolo[3,2-c]pyridin-4-one derivatives as pfk inhibitors useful for the treatment of protozoal infections
JP6522502B2 (ja) Ｗｎｔシグナル阻害剤
US20090270442A1 (en) Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
BR122024019819A2 (pt) Compostos de aminoácidos, seus usos e composição farmacêutica dos mesmos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired